Microdosing GLP-1 (glucagon-like peptide-1) agonist weight loss drugs involves taking smaller doses of semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), or orforglipron (Foundayo) than recommended by the U.S
While genetic predisposition does not predict exact medication response, understanding your peptide pathway genetics can support a more informed conversation with your provider about whether aggressive dose escalation or a microdose protocol might suit your biochemistry
Ongoing support includes digital follow-ups, dosage optimization, and progress tracking
As a plastic surgeon, Im witnessing firsthand the surge in GLP-1 usage for weight lossand the unexpected impact it has on skin health, said Dr
Its the first obesity drug doctors are allowed to prescribe specifically to reduce the risk of heart and circulatory disease in people living with excess weight or obesity, according to the UK Medicines and Healthcare products Regulatory Agency (MHRA)
Chuong et al
